Interferon beta 1b following natalizumab discontinuation: One year, randomized, prospective, pilot trial

BMC Neurology

Volumn 13, Issue , 2013, Pages

  Gobbi, Claudio ^a   Meier, Dominik S ^b   Cotton, François ^c,d   Sintzel, Martina ^e   Leppert, David ^f   Guttmann, Charles R G ^b   Zecca, Chiara ^a  

^a REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITÉ LYON 1   (France)

^d UNIVERSITÉ DE LYON   (France)

^e MCS Medical Communication Services   (Switzerland)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

De escalation; Interferon beta1b; Multiple sclerosis; Natalizumab; Progressive multifocal leukoencephalopathy

Indexed keywords

GADOLINIUM; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISABILITY; DISEASE ACTIVITY; DISEASE FREE INTERVAL; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; INFECTION; INJECTION SITE REACTION; INTENTION TO TREAT ANALYSIS; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; RECURRENT DISEASE; RELAPSE; RISK ASSESSMENT; SINGLE BLIND PROCEDURE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT DURATION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GADOLINIUM; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PILOT PROJECTS; YOUNG ADULT;

EID: 84880932932     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-13-101     Document Type: Article

References (16)

1. Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patients selection and monitoring. Lancet Neurol 2011, 10:745-758. 10.1016/S1474-4422(11)70149-1, 21777829.
2. Cada DJ, Levien T, Baker DE. Natalizumab. Hosp Pharm 2005, 40:336-346.
3. O'Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurol 2011, 76:1858-1865.
4. Killestein J, Vennegoor A, Strijbis EM, et al. Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol 2010, 68(3):392-395. 10.1002/ana.22074, 20661928.
5. West TW, Cree BA. Natalizumab dosage suspension: are we helping or hurting?. Ann Neurol 2010, 68(3):395-399. 10.1002/ana.22163, 20818793.
6. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the " McDonald Criteria". Ann Neurol 2005, 58:840-846. 10.1002/ana.20703, 16283615.
7. Moraal B, van den Elskamp IJ, Knol DL, et al. Long-interval T2-weighted subtraction magnetic resonance imaging: A powerful new outcome measure in multiple sclerosis trials. Ann Neurol 2010, 67:667-675.
8. Khatri BO, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurol 2009, 72(5):402-409.
9. Havla J, Gerdes LA, Meinl I, et al. De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. J Neurol 2011, 258(9):1665-1669. 10.1007/s00415-011-5996-y, 21431380.
10. Vellinga MM, Castelijns JA, Barkhof F, et al. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurol 2008, 70:1150-1151.
11. Fox RJ, Kappos L. Is natalizumab overshooting its rebound?. Neurol 2008, 70:1173-1174.
12. Fox R, Kappos L, Cree B, et al. Effects of a 24-week natalizumab treatment interruption on clinical and radiological parameters of multiple sclerosis disease activity: the RESTORE study. Mult Scler J 2011, 17(S10):S509-S510.
13. Rossi S, Motta C, Studer V, et al. Effect of Glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab. Eur J Neurol 2012, 20(1):87-94.
14. Magraner MJ, Coret F, Navarré A, et al. Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-months observational study. J Neurol 2011, 258(10):1805-1811. 10.1007/s00415-011-6019-8, 21625938.
15. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Annal Neurol 2001, 49:270-277.
16. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354:899-910. 10.1056/NEJMoa044397, 16510744.